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Summary
Chronic renal failure (CRF) causes alterations in calcium-phos-
phate metabolism promoting the development of secondary
hyperparathyroidism (HPT) and renal osteodystrophy. Recent
data suggest that these alterations may play a crucial role in
determining cardiovascular calcifications and, thus, cardiovas-
cular mortality among CRF patients. An impaired 1α-hydroxy-
lation of 25-hydroxycholecalciferol (25(OH)D) to 1,25-dihy-
droxycholecalciferol (1,25(OH)2D) with decreased circulating
1,25(OH)2D levels is commonly observed in patients with crea-
tinine clearance below 70 ml/min. The reduction in 1,25(OH)2D
production triggers the upregulation of PTH synthesis, through
a decreased suppression on PTH gene transcription and a de-
creased intestinal calcium absorption. Low vitamin D stores of-
ten contribute to the decrease in production and tissue resis-
tance to vitamin D worsens 1,25(OH)2D deficiency. A reduced
expression of vitamin D receptor (VDR) and a less efficient
binding of the complex 1,25(OH)2D-VDR to specific DNA seg-
ments account for the resistance to 1,25(OH)2D in target cells.
Thus, absolute and relative 1,25(OH)2D deficiency is one of the
causes of secondary HPT in patients with CRF, together with
phosphate retention and skeletal resistance to PTH. 
Consistently with these pathophysiological mechanisms, the
therapeutic use of 1,25(OH)2D still represents a milestone for
the treatment of uremic secondary HPT and renal osteodystro-
phy, even though hypercalcemia and hyperphosphatemia are
common adverse events and may increase the risk of cardio-
vascular calcifications. Furthermore, adynamic bone disease
may develop after vitamin D therapy. Low levels of serum
25(OH)D are associated with more severe osteodystrophy and
HPT, even among dialysis patients. To separate these adverse
effects from anti-PTH activity, 1,25(OH)2D analogues with low-
er hypercalcemic effect have been synthesized and are now
available for clinical use.
KEY WORDS: vitamin D, calcium, parathyroid hormone, phosphate, chronic
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Vitamin D metabolism
Cholecalciferol (vitamin D3) and ergocalciferol (vitamin D2) de-
rive from dietary sources (animal and fish liver, eggs, fish oils).
Cholecalciferol is also produced in the skin from 7-dehydrocho-
lesterol (pre-vitamin D3), through the nonenzymatic effect of
sunlight ultraviolet B rays (UVB, wavelengths 295-305 nm). 7-
dehydrocholesterol is mostly stored in the cytoplasm of cells at
the dermal-epidermal border and the effectiveness of its con-
version to cholecalciferol is related to the amount of photochro-
matic energy entering the skin. Photochromatic energy pene-
trating the skin greatly depends from the incident angle of UVB
rays: in winter, the shallow incident angle of sunlight results in
lower energy reaching the epidermis and dermis and, there-
fore, in lower production of vitamin D3. 
Cholecalciferol, ergocalciferol are hydroxilated at carbon 25 in
the liver and at carbon 1 in kidney tubules thanks to enzymatic
systems including cytocrome P-450 and located at the inner
mitochondrial membrane. PTH and hypophosphatemia en-
hance the activity of renal 1α-hydroxylase, but not that of liver
25-hydroxylase. 
The final product, 1,25-dihydroxycholecalciferol (1,25(OH)2D),
is the active metabolite of vitamin D, although its serum con-
centrations do not correlate with vitamin D stores. 1,25(OH)2D
promotes active and passive intestinal absorption of calcium
and phosphate, and bone mineralization. Conversely,
1,25(OH)2D suppresses PTH synthesis and parathyroid cell
proliferation through a genomic activity. 1,25(OH)2D2 and
1,25(OH)2D3 have the same potency in activating intestinal cal-
cium absorption and bone mineralization, whereas
1,25(OH)2D2 is less potent in suppressing parathyroid gland
activity (1). Genomic effect of 1,25(OH)2D is modulated by spe-
cific cytosolic receptors for vitamin D (VDR) in target cells.
VDR forms a heterodimer with the retinoid X receptor that en-
ables the complex 1,25(OH)2D-VDR to bind with high affinity to
the vitamin D response element (VDRE) on the transcription
promoters of vitamin D-sensitive genes. VDR has been detect-
ed in vitamin D-sensitive tissues (bone, intestine, kidney and
parathyroid glands) and even in tissues where vitamin D activi-
ty is still unclear (myocardium, brain, pancreas and testis). In
addition to the genomic effect, a rapid non-genomic effect of
1,25(OH)2D was found in intestinal cells.
The monohydroxylated metabolite, 25-hydroxycholecalciferol
(25(OH)D), is 500 times less active than 1,25(OH)2D, but its
serum concentration is the best indicator of vitamin D body
stores. In spite of its low affinity for VDR, 25(OH)D maintains
some biological effects, because its serum concentrations are
1000 times higher than those of 1,25(OH)2D and compensate
for the low affinity for VDR (2). The physiopathological rele-
vance of 25(OH)D has been recently revaluated in population
studies showing that low serum concentrations of 25(OH)D
were associated with higher serum PTH in healthy elderly indi-
viduals (3, 4). In these studies, the serum 25(OH)D concentra-
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tion above which all values of serum PTH were normal, was 30
ng/ml (75 nmol/L). This threshold for secondary hyperparathy-
roidism (HPT) was also confirmed in elderly individuals with el-
evated creatinine clearance (5) and in hemodialysis patients
(6, 7). Based on these findings, the normal range of 25(OH)D
serum concentrations was recently redefined and concentra-
tion above 30 ng/ml (75 nmol/L) are now generally recom-
mended to prevent secondary HPT (4, 8). Lower 25(OH)D
serum concentrations were associated with increased risk of
fracture and low bone mineral density (BMD) at different bone
sites in young and elderly healthy individuals of both sexes (9,
10). Accordingly, osteopenia and osteoporosis were more fre-
quent in patients with 25(OH)D serum concentrations below 30
ng/ml (75 nmol/L) and osteomalacia was found in patients with
25(OH)D concentrations below 10 ng/ml (25 nmol/L) (4, 8, 11).
Serum 25(OH)D concentrations of 30 ng/ml (75 nmol/L) or
higher were proposed as the target for the treatment of os-
teodystrophy, even in hemodialysis patients (6, 7). Hemodialy-
sis patients with lower levels of 25(OH)D had more marked
Looser’s zone on X-rays and decreased bone formation at
bone histology regardless of 1,25(OH)2D levels (12, 6). Howev-
er, excessively high 25(OH)D levels were associated with low
turnover osteodystrophy. Thus, concentrations between 20 and
40 μg/ml have been proposed as the most appropriate
25(OH)D target range for hemodialysis patients by other au-
thors (12). The need to maintain normal vitamin D stores sug-
gests that unknown vitamin D metabolites, besides 1,25(OH)2D,
may have a beneficial effect on bone and parathyroid metabo-
lism in end stage renal disease. 
Vitamin D may have important functions besides mineral ion
homeostasis (13). In patients with congestive heart failure,
1,25(OH)2D concentrations were found to be significantly re-
duced (14). Recently, it has been demonstrated that vitamin
D therapy decreased myocardial hypertrophy in dialysis pa-
tients (15). Moreover, vitamin D replacement downregulates
the renin-angiotensin system and controls blood pressure in
VDR knock-out mice (16). Paradoxically, low 1,25(OH)2D lev-
els have been correlated with increased coronary calcification
in patients at high risk for coronary heart disease (17). In-
deed, many epidemiological studies have documented an as-
sociation between vitamin D deficiency and autoimmune dis-
eases, several types of cancers, and cardiovascular disease
(18, 19).
Pathogenesis of secondary hyperparathyroidism 
in chronic renal failure (CFR)
Parathyroid cells are characterized by a low turnover and
rarely undergo mitoses (20, 21). However, in the presence of
low calcium, high phosphorus, vitamin D deficiency, and ure-
mia, parathyroid cells leave quiescence and divide by increas-
ing the activity of regulatory cell cycle enzymes and/or their in-
hibitors (22, 23). In secondary HPT, parathyroid gland growth
is initially diffuse and polyclonal. Cell proliferation in the nod-
ules then becomes monoclonal and aggressive (24). The rapid
de-differentiation of hyperplastic parathyroid cells in culture
(25) precludes further assessment of the relative contribution
of changes in calcium, phosphate, and vitamin D to the expres-
sion of components of the cell cycle critical for growth control.
Role of phosphate 
Hyperphosphatemia due to decreased glomerular filtration rate
is an important factor in the pathogenesis of secondary HPT
(26). Elevated serum phosphate levels induce secondary HPT
through indirect and direct mechanisms (27). In addition, hy-
perphosphatemia inhibits 1,25(OH)2D production (28), with
subsequent hypocalcemia.
The direct effects of phosphorus have been demonstrated both
in vitro and in vivo studies. High phosphorus concentrations
stimulate PTH secretion in intact rat parathyroid glands (29).
Unfortunately, the in vitro effects of phosphorus on PTH secre-
tion could be observed in intact parathyroid tissue prepara-
tions, but not isolated, dispersed parathyroid cells (12, 30). Re-
cently, several studies have shown that phosphate may regu-
late parathyroid function at post-transcriptional level, as it im-
proves PTH mRNA stability through binding of parathyroid cy-
tosolic proteins to the 3’-UTR and especially to the terminal 60
nucleotides of PTH mRNA (31).
Two weeks after 5/6 nephrectomy in rats, uremia-induced mi-
totic activity is further enhanced by high dietary phosphate, but
prevented by phosphorus restriction (22). In contrast to the mi-
togenic effects of hyperphosphatemia, dietary phosphorus re-
striction appears to counteract the proliferative signals induced
by uremia, thus preventing parathyroid cell replication and the
increase in parathyroid gland size (32).
Table I - Values of the parameters of calcium-phosphate metabolism in patients with different creatinine clearance. A significant decrease of
serum 1,25(OH)2D is observed since creatinine clearance values of 70 mL/min and is associated with secondary HPT. Serum phosphate in-
creases later, but occurs in the early stages of CRF. Intestinal calcium absorption decreases during the progression of CRF. It was mea-
sured using strontium (Sr) as a marker: strontium absorption was determined 4 hours after an oral load and expressed as area under the
time-plasma strontium concentration curve (90).
N. 9 10 11 10 18
Creatinine clearance (mL/min) <20 21-40 41-60 61-80 >80
Age (years) 56±4.7 56±3.4 59±2.6 50±5.5 52±2.1
Serum phosphate (mmol/L) 1.8±0.09 1.26±0.07 1.17±0.05 1.12±0.05 1.1±0.04
Plasma calcium (mmol/L) 2.08±0.1 2.38±0.03 2.42±0.03 2.35±0.03 2.35±0,02
Serum 1,25(OH)2D 15±2.9 21±3.2 23±3.6 28±2.9 39±2.8
iPTH (pg/ml) 494±120 129±37 47±7 63±12 29±3
Enteral Ca absorption
(mmol of absorbed Sr/l per min) 3.4±0.4 6.2±0.9 6.1±0.4 7.6±0.7 8.1±0.6
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Recent studies on the effects of dietary phosphate on parathy-
roid gland growth demonstrated that the low phosphorus-in-
duction of p21 (an inhibitor of kinases of the cell-cycle) mRNA
and protein content in parathyroid glands contributes to the an-
tiproliferative effects of phosphate restriction on uremia-in-
duced parathyroid cell growth (33). In this uremic rat model,
the temporal increases in p21 protein expression correlate in-
versely with the parathyroid levels of a marker of mitotic activi-
ty, the proliferating nuclear cell antigen (PCNA) (33). 
In the search for the mitogenic stimuli triggered by high dietary
phosphate, we next focused on transforming growth factor-α
(TGFα). TGFα, known to promote growth not only in malignant
transformation but also in normal tissues (34), is increased in
hyperplastic and adenomatous human parathyroid glands (35).
High phosphate diet worsens uremia-induced parathyroid hy-
perplasia by increasing parathyroid expression of TGFα. The
rapid return of parathyroid TGFα content to normal after phos-
phate restriction suggests that low phosphorus may counteract
uremia-induced parathyroid cell growth not only through induc-
tion of p21 expression, but also by preventing the increase in
parathyroid TGFα (33, 36). 
Increase in parathyroid TGFα induces cell growth through au-
tocrine and paracrine mechanisms through activation of its re-
ceptor, the epidermal growth factor receptor (EGFR) (37). In
human parathyroid glands, Gogusev et al. (35) demonstrated
the presence of EGFR protein in 4 out of 5 adenomas, in 13
out of 15 tissue samples of hyperplasia secondary to renal fail-
ure, and in most samples of normal parathyroid tissue. No dif-
ferences in the expression patterns were observed between
groups. However, studies in 104 human hyperplastic parathy-
roid glands, which failed to detect EGFR protein, showed high-
er EGFR mRNA expression in carcinoma and primary hyper-
plasia compared to adenomas and hyperplasia secondary to
renal failure (38). 
The concept that co-expression of TGFα and EGFR could con-
tribute to non-neoplastic parathyroid hyperplasia led us to ex-
amine the dietary-phosphate regulation of parathyroid EGFR
expression in rat parathyroid glands. Similarly to the changes
in TGFα expression, high dietary phosphate increases parathy-
roid EGFR content to above normal levels, while phosphorus
restriction prevented the increases in EGFR levels (39, 40). 
These findings indicate that the uremia-induced parathyroid co-
expression of TGFα and its receptor, EGFR, acts as a mito-
genic signal, which can be blunted by phosphate restriction
and counteracted through the induction of p21. These new in-
sights into the molecular mechanisms of parathyroid hyperpla-
sia suggest that, in addition to phosphate restriction or use of
phosphate binders, therapeutic approaches focusing on induc-
tion of p21 and inactivation of TGFα/EGFR growth-promoting
signals may slow down the progression of secondary HPT.
Role of calcium 
Calcium is a key regulator factor in secondary HPT progression.
Low serum calcium levels decrease the activation of the Calci-
um-Sensing Receptor (CaSR), a plasma membrane G-protein
coupled molecule that allows parathyroid cells to sense calcium
in the extracellular fluid, thus greatly promoting PTH synthesis
and secretion (41). In contrast, hypercalcemia activates the
CaSR, rapidly suppressing secondary HPT. Recent evidence
suggests that signaling through the CaSR plays an important
role on parathyroid hyperplasia (42). Moreover, calcium-depend-
ing signaling through the CaSR may prevent parathyroid hyper-
plasia even in tissues that are not-responders to vitamin D (43). 
The extracellular calcium concentration may also regulate the
level of PTH mRNA (44, 45) and parathyroid cell proliferation
(46). Moreover, calcium regulates VDR mRNA and protein ex-
pression in parathyroid cells independently of 1,25(OH)2D (47).
Clearly, serum calcium levels could also indirectly regulate
PTH levels through a feedback of 1,25(OH)2D on the parathy-
roid glands. 
Reduced expression of CaSR in hyperplastic parathyroid
glands has been demonstrated in an animal model (48).
Parathyroid hyperplasia appears 48 hours after 5/6 nephrecto-
my in rats fed a high phosphate diet, while CaSR expression
starts to decrease 48 hours later. Furthermore, in humans,
CaSR content declines by about 60% in hyperplastic parathy-
roid glands compared to normal controls (49).  
Further support for the pathophysiological relevance of changes
in the expression of parathyroid p21, TGFα and EGFR in con-
trolling proliferative activity came from studies, evaluating the
expression of these three proteins after suppression of
parathyroid cell growth by high-calcium intake or its further en-
hancement by low dietary calcium. High dietary calcium con-
trolled uremia-induced parathyroid hyperplasia, reducing both
parathyroid gland size and the expression of two markers of
mitotic activity, Ki67 and PCNA (36). Furthermore, high calcium
diet increased parathyroid p21 levels and prevented the rise in
parathyroid content of TGFα and EGFR induced by uremia
(36, 40). The mechanisms for high-calcium induction of p21
and prevention of the increase in TGFα and EGFR are un-
known. Studies in vitamin D receptor-ablated mice showed the
ability of a calcium-enriched diet to prevent the development of
parathyroid hyperplasia in both hypocalcemic and normacal-
cemic states (50). 
In relation to high-calcium control of TGFα/EGFR growth pro-
moting signal, hypercalcemia and low plasma levels of TGFα
were recently associated in cancer patients, suggesting the
possibility of the systemic control of TGFα expression by calci-
um (51). The existence of such an association in CRF patients
could partially explain the suppression of parathyroid growth by
hypercalcemia. 
The changes in p21, TGFα and EGFR in the parathyroid
glands of uremic rats fed a high Ca diet suggest that increases
in serum calcium or in intracellular calcium, induced by vitamin
D therapy, could enhance the effects of vitamin D itself in in-
creasing p21 expression and reducing TGFα and EGFR con-
tent.
Role of vitamin D
In the 5/6 nephrectomized rats, 1,25(OH2)D3 suppresses ure-
mia-induced parathyroid cell proliferation both in vitro (52), and
in vivo (53). 
Naveh-Many showed that PTH mRNA was much higher in
parathyroid glands from vitamin D-deficient normocalcemic rats
than controls, and that in vitamin D-deficient hypocalcemic rats
the upregulation of PTH mRNA was even more pronounced
(54). Moreover, many studies have been conducted to assess
whether supplementation with vitamin D sterols can prevent or
ameliorate secondary HPT in CRF.
In the early-uremia rat model (7 days of renal failure), 1,25(OH2)D
and the less hypercalcemic vitamin D analog 1,25-dihydroxy-
19-norvitamin D2 (19-norD2) controlled both serum PTH levels
and parathyroid hyperplasia similarly to what is described with
phosphate restriction (36). The suppression of uremic rat
parathyroid cell growth by vitamin D treatment can be partially
accounted for by the increased expression of p21. Further-
more, studies in patients with secondary HPT suggest an im-
portant role for increased p21 expression in parathyroid growth
arrest (55). 
The efficacy of either 1,25(OH2)D or 19-norD2 to arrest parathy-
roid hyperplasia and parathyroid gland enlargement, was associ-
ated with prevention of TGFα and EGFR expression in the
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parathyroids (39). Since the TGFα activation of its receptor in-
duces both TGFα and EGFR gene expression, it is also possible
that 1,25(OH)D inhibition of EGFR activation mediates the sup-
pressive effects of the sterol on TGFα and EGFR expression
(56).
In addition, vitamin D therapy suppresses parathyroid growth
even in an established rat model of secondary HPT. 5/6
nephrectomized rats fed a high phosphorus diet for 8 weeks
and received either vehicle or the vitamin D analog 19-norD2.
No increase in parathyroid gland size was observed in the vita-
min D treated uremic animals compared to the untreated rats
(36).
In patients with CRF (Table I), the inability to synthesize
1,25(OH)2D is sustained by decreased 1α-hydroxylation of
25(OH)D in tubular cells and occurs prior to the increase in
PTH secretion (57). Serum concentrations of 1,25(OH)2D start
to decrease at values of creatinine clearance near 70 mL/min.
Therefore, patients are predisposed to secondary HPT even in
the early phases of CRF (58). Because vitamin D sensitises
the parathyroid gland to calcium, it is possible that vitamin D
deficiency in early CRF may contribute to the development of
secondary HPT, even in the absence of overt hypocalcemia. 
Alteration of renal 1α-hydroxylase is frequently associated with
other defects that may further diminish 1,25(OH)2D synthesis.
A reduction in vitamin D stores may be found in a significant
proportion of CRF patients, but also of healthy individuals in in-
dustrial countries (3, 59). Among healthy elderly Europeans
36% of men and 47% of women had serum 25(OH)D levels
below 12 ng/mL (30 nmol/L), with the highest prevalence in
Southern countries (60, 61). Similar frequencies were also ob-
served in non-European populations (62, 11). Ninty-three per-
cent of Spanish elderly individuals with plasma creatinine high-
er than 1 mg/dL, and 79% of Italian patients with creatinine
clearance between 30 and 70 mL/min, had serum 25(OH)D be-
low 30 ng/ml (75 nmol/L) (5, 63). In these populations, 25(OH)D
deficiency was not necessarily associated with a decrease in
serum concentrations of 1,25(OH)2D (5). Inactivity with insuffi-
cient exposure to sunlight or low dietary intake may be respon-
sible for vitamin D insufficiency in CRF patients. Patients with
CRF may also develop a reduced capability to produce
25(OH)D and resistance to UVB, due to skin hyperpigmenta-
tion caused by retention of melanocyte-stimulating hormone.
An additional factor may be patient’s age, since aging is usual-
ly associated with lower skin concentration of 7-dehydrocholes-
terol and decreased responsiveness of renal 1α-hydroxylase to
PTH (64). Underlying renal disease may also affect vitamin D
status. Urinary loss of vitamin D bound to vitamin D-binding
protein occurs in nephrotic syndrome. Likewise, patients un-
dergoing peritoneal dialysis lose vitamin D-binding protein with
peritoneal effluent. 
1,25(OH)2D concentrations were directly related with those of
25(OH)D in CRF patients (62), but not in healthy individuals.
Thus, the activity of renal 1α-hydroxylase in CRF appears to
be substrate-dependent and is depressed by low serum con-
centrations of 25(OH)D (63, 62, 65). Interestingly, a positive
correlation between 25(OH)D and 1,25(OH)2D was also ob-
served in hypercalciuric stone formers with normal creatinine
clearance (66). Therefore, careful assessment of 25(OH)D sta-
tus is today proposed as an integral part of the therapeutic
strategy to prevent secondary HPT and bone disease in CRF
patients.
Clinical consequences of secondary hyperparathyroidism
Secondary HPT causes both skeletal and extra-skeletal com-
plications. Bone-associated consequences include with osteitis
fibrosa and renal osteodystrophy, while non-skeletal conse-
quences include cardiovascular calcification, soft-tissue calcifi-
cation, endocrine disturbances, compromised immune system,
neurobehavioral changes, and altered erythropoiesis (67, 68).
Renal osteodystrophy  
Renal osteodystrophy refers to a bone disorder that occurs in
patients with CRF, characterized by abnormal bone turnover
(69). PTH directly stimulates calcium mobilization from the
bone by acting on the osteoclasts and indirectly by stimulating
bone resorption and formation through the increase of vitamin
D synthesis in the kidney. It is well known that vitamin D stimu-
lates osteoblast activity and increases both osteoclast amount
and function (69). In CRF patients vitamin D deficit leads to a
loss in normal osteoblast activity and a reduction in bone min-
eralization. Furthermore, high serum PTH levels stimulate os-
teoclasts to mobilize more calcium from bone tissue, with bone
mass reduction (70, 71). 
In CRF patients renal osteodystrophy is characterized by five
types of bone lesions. Osteitis fibrosa and mixed osteodystro-
phy are high-turnover bone diseases. Osteomalacia, alumini-
um-induced bone disease, and adynamic bone disease are
low-turnover bone diseases (69). High-turnover bone diseases
are characterized by rapid bone turnover induced by abnormal-
ly high serum PTH levels and abnormal mineralization. Con-
versely, low-turnover bone diseases are caused by over-sup-
pression of PTH or aluminium at the site of bone mineralization
(69). Figure 1 displays the complex interaction among the mul-
tiple factors that may cause the different bone lesions in renal
osteodystrophy.
Cardiovascular calcification 
CRF patients have a dramatically higher incidence of cardio-
vascular morbidity and mortality compared to the general pop-
ulation. In the last ten years, several studies pointed out that
vascular calcification is a major cause of cardiovascular dis-
ease in the dialysis population. In CRF patients, high levels of
plasma calcium, serum phosphate and PTH play a critical role
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Figure 1 - This figure displays the complex interaction between the dif-
ferent components of the system controlling calcium and phosphate in
blood. The decrease of glomerular filtration rate (GFR) leads to phos-
phate retention and 1,25(OH)2D deficiency that induce parathyroid hy-
perplasia and stimulate PTH secretion. Various endogenous or exoge-
nous toxins interfere with bone mineralization processes.
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in the pathogenesis of cardiovascular events.
Patients develop extensive medial calcification, which causes
increased arterial stiffness and high morbidity and mortality
due to cardiovascular events (72, 73). A variety of risk factors
are associated with vascular calcification in dialysis patients
(time on dialysis, uremic toxins, history of diabetes, inflamma-
tion), but abnormalities in bone mineral metabolism may play a
critical role (74). In fact, elevated serum phosphate, calcium-
phosphate product, and PTH levels contribute to vascular cal-
cification, although their roles are incompletely understood (75,
76). 
Elevations of serum phosphate and calcium-phosphate product
levels may worsen cardiovascular events in the uremic popula-
tion, through a progressive increase in calcium deposition in
the coronary arteries and heart valves (77). Furthermore, calci-
um-containing phosphate binders can increase calcium load
(78). Recently, an elegant study by Goodman et al. (79) in he-
modialysis children and young adults showed a correlation be-
tween coronary artery calcification detected by electron beam
computed tomography (EBCT) and age of dialysis, serum
phosphorus, calcium-phosphate product levels, and daily in-
take of calcium. Moreover, experimental observations in uremic
rats (80, 81) and in dialysis patients (82) showed that a new
calcium and aluminium-free phosphate binder (Sevelamer HCl)
reduced the progression of cardiovascular calcification more
than calcium-based phosphate binders. 
Treatment of secondary hyperparathyroidism: 
role of vitamin D and its analogues
Prevention and treatment of secondary HPT commonly re-
quires control of both phosphate and 1,25(OH)2D levels in
serum. Phosphate levels are usually controlled by reducing di-
etary phosphate intake, by dialysis, and by using phosphate-
binders. 1,25(OH)2D effectively suppresses PTH production
and improves bone histology in some patients (77). Vitamin D
and its analogues act after binding to VDR in parathyroid cell
cytosol. The vitamin D-VDR complex controls the rate of PTH
gene transcription by interacting with VDRE, located 100-120
bases upstream from the PTH gene (83). Furthermore, vitamin
D upregulates CaSR expression on cell membrane, thus lead-
ing to a greater inhibition on PTH secretion (41). Through
CaSR the increase in circulating calcium ions can inhibit tonic
PTH secretion by stimulation of mitogen-activated protein ki-
nase pathways (84). VDRE regions are present in the two pro-
motors of the CaSR gene (85). Calcium ions inhibit PTH secre-
tion not only through CaSR, but also by interacting with cytoso-
lic proteins affecting the stability of PTH mRNA. Hypocalcemia
favors the activity of cytosolic proteins protecting PTH mRNA
from the degrading effect of ribonucleases. On the other hand,
hypercalcemia favors the activity of proteins degrading PTH
mRNA (86). Furthermore, a trascriptional activity of calcium
has been hypothesized (87). Postranscriptional and transcrip-
tional effects of calcium ions are indirectly influenced by the
calcium-repleting activity of vitamin D. 
The therapeutic use of 1,25(OH)2D in CRF mainly aims to raise
intestinal absorption of calcium, to protect bone against osteo-
malacia and to control parathyroid function. However, also the
function of other organs expressing VDR, as kidney, pancreas,
myocardium and testis, might be improved by vitamin D admin-
istration. 1,25(OH)2D inhibitory effect on PTH synthesis and
parathyroid hyperplasia is well established in CRF. Vitamin D
analogues with a lower hypercalcemic and hyperphosphatemic
activity, are now available as an efficient alternative to
1,25(OH)2D treatment. Furthermore, normal serum levels of
25(OH)D are relevant for the prevention or treatment of sec-
ondary HPT, due to the capacity of 25(OH)D to support renal
1α-hydroxylase activity or the synthesis of active vitamin D
metabolites different from 1,25(OH)2D (6, 62, 63, 65). 
Clinical targets for serum concentrations of phosphate, calcium
and PTH (Table II) have been proposed in the 2003 guidelines
proposed by the Kidney Dialysis Outcomes Quality Initiative
(K/DOQI) Work Group (88). Target for plasma concentrations
of PTH increases according to creatinine clearance because
patients develop a progressive tissue resistance to PTH ex-
plained by a diminished expression of PTH receptors and by
1,25(OH)2D deficiency or resistance (89, 90). The low target
for calcium concentrations aims to avoid calcium overload and
an excessively high calcium-phosphate product. 
A particular bone complication of the therapy with vitamin D
metabolites occurs in case of excessive parathyroid suppres-
sion. As defined in the K/DOQI guidelines, the target for PTH
concentration is 150-300 pg/mL in end-stage CRF (Table II). If
the values of circulating PTH are suppressed below these lim-
its, bone cells become quiescent and bone remodeling is far
slowed (91). The histology pattern of these functional alter-
ations is adynamic bone disease, characterized by decreased
number of bone cells, bone metabolic inactivity and reduced
bone formation rate (91). The mechanism of adynamic bone
disease is unknown. The clinical consequences of adynamic
bone disease may be an increased fracture risk, while its rela-
tionship with osteoporosis is still debated (92). At the opposite,
osteomalacia may develop in case of 1,25(OH)2D deficiency,
even though the toxic effect of aluminum overload has been
the most frequent cause of osteomalacia in dialysis population
till some years ago (93).
Vitamin D supplementation
Vitamin D deficit is frequent in CRF and its correction prevents
or cures secondary HPT and achieves the specific beneficial
effects of 25(OH)D on muscles and bones (6, 94). Vitamin D
supplements are recommended in patients with creatinine
clearance above 15 mL/min and with serum concentrations of
25(OH)D below 30 ng/mL (75 nmol/L), because their kidney is
stimulated to produce 1,25(OH)2D by the increase of 1α-hy-
droxylase substrate, 25(OH)D. Ergocalciferol is the most con-
venient product to replace vitamin D stores, due to its availabil-
ity, cost and efficacy. K/DOQI guidelines recommend to admin-
ister 50000 IU/month per six months orally in patients with
serum 25(OH)D concentrations of 16-30 ng/mL (40-75 nmol/L),
or six-month courses with more frequent doses in the presence
of lower 25(OH)D levels (88). During this treatment, plasma
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Table II - Objectives for renal osteodystrophy treatment in patients
with different levels of CRF recommended in K/DOQI guidelines.
Stage 1 and 2 of renal function are characterized by creatinine
clearance above 90 mL/min and between 60 and 90 mL/min. 
Stage of renal function
Stage 5 Stage 4 Stage 3
Creatinine clearance (mL/min) <15 16-30 30-60
iPTH (pg/mL) 150-300 70-110 35-70
Serum phosphate (mmol/L) 1.13-1.78 0.87-1.49 0.87-1.49
Plasma calcium (mmol/L) 02.1-2.37 2.2-2.5 2.2-2.5
Ca-P product (mmol2/L2) < 4.5 < 4.5 < 4.5
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calcium concentration should not exceed 2.51 mmol/L (10.5
mg/dL) and serum phosphate 1.49 mmol/L (4.6 mg/dL). To
prevent vitamin D deficiency in CRF patients, Schomig and
Ritz proposed oral supplementation with 1000 IU day of chole-
calciferol, or 10000 IU/week (58). Alternatively, 25(OH)D may
be administered orally at the dose of 10-40 μg/day, according
to the serum levels of this metabolite and calcium, as usually
employed in osteoporosis. 
The use of vitamin D in end-stage CRF has been source of de-
bate. Hemodialysis patients with low levels of 25(OH)D had
more marked Looser’s zones at the pelvis radiograms and de-
creased bone formation at bone histology, regardless of
1,25(OH)2D levels (12, 6). Gazali et al. suggest to prescribe
1600 IU/day of vitamin D or 20-30 μg/day of 25(OH)D at least
during the winter months (6). The doses of vitamin D proposed
by these Authors were higher than those commonly indicated
for general elderly population (800 IU/day), because the need
of vitamin D is increased in CRF patients due to less efficient
25(OH)D synthesis (2, 123).
1,25(OH)2D
1,25(OH)2D remains a milestone for the treatment of sec-
ondary HPT in CRF patients. It may be prescribed to patients
with secondary HPT at every stage of CRF, although theoreti-
cally it should be used in the presence of normal serum levels
of 25(OH)D. Exogenous administration of 1,25(OH)2D be-
comes inevitable in patients with creatinine clearance below 15
mL/min (Table III), provided that the serum values of calcium,
phosphate and PTH indicate its use (88). In CRF patients with
creatinine clearance above 15 mL/min, 1,25(OH)2D treatment
may begun at the oral dose of 0.25 μg/day, according to the
K/DOQI guidelines (88). Clinical trials aimed to study the out-
come of 1,25(OH)2D treatment showed that CRF patients, who
had received 1,25(OH)2D (0.25-0.5 μg/day per os) for one
year, had lower circulating PTH and normal bone histology at
the end of follow-up. A significantly higher bone turnover and
lower bone mineral density were observed in patients who had
not received 1,25(OH)2D (95-97). Therefore, although protec-
tive against HPT, 1,25(OH)2D treatment is likely to expose pa-
tients with early CRF to the risk of adynamic bone disease and
may also accelerate renal function decline, probably due to
vascular deposition of calcium-phosphate salts (98). However,
the dosage of 0.125-0.25 μg/day was well tolerated in patients
with mild-moderate CRF and appeared safe for bone and kid-
ney (99, 100).
1,25(OH)2D is prescribed to hemodialysis patients as oral daily
doses or intravenous (i.v.)/oral thrice-weekly boli. The intermit-
tent supplementation was studied for dialysis patients with the
rationale to produce peaks of 1,25(OH)2D concentration in
blood. Pharmacokinetic considerations and experimental find-
ings suggested that intermittent supplementation has the ad-
vantage of a greater PTH suppression and an easier patient
compliance. In spite of this promising background, two trials
comparing intermittent with daily administration of 1,25(OH)2D
in dialysis patients, showed no advantages of intermittent dos-
es in terms of efficacy and safety (101, 102). About i.v. or oral
boli, although K/DOQI guidelines conclude that i.v. boli were
more efficient for the control of secondary HPT, a study was
unable to find differences between the two administration
routes (103). The expectation created by the introduction of the
intermittent administration gave rise to a discussion about a
possible “pharmacological parathyroidectomy”, capable to
abolish autonomous parathyroid secretion. Conversely,
nephrologists learnt that excessive suppression of PTH was
the main cause of adynamic bone disease (121, 122). Plasma
concentrations of PTH between 150 and 300 pg/mL are now
considered as the target for vitamin D treatment which has to
be started only when PTH is above this range. 
Vitamin D analogues
Several new vitamin D analogues have been developed and
investigated with the rationale to treat secondary HPT decreas-
ing the risk of hypercalemia and hyperphosphatemia in CRF
patients (83, 84). Vitamin D analogues have variable affinity for
the components of the vitamin D system, including the vitamin
D-binding protein and the nuclear VDR. Some of the effects
are genomic and mediated through changes in the structural
configuration of the vitamin D-VDR complex or in the affinity of
the vitamin D-VDR complex for the key response elements in
various target genes. There are currently three vitamin D ana-
logues approved for use in CRF patients with secondary HPT
in the US, 1,25-dihydroxy-22-oxavitamin D3 (22-oxacalcitriol,
OCT), 1,25-dihydroxy-19-norvitamin D2 (19-norD2), 1α-hydrox-
yvitamin D2 (1αOHD2). 19-norD2 is approved for the treatment
of secondary HPT in Italy.
OCT is a vitamin D3 derivate, which differs from 1,25(OH)2D3
for the substitution of carbon 22 with an oxygen. Oral and i.v.
preparations are available. Experience in rats showed that it is
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Table III - Algorithm for treatment with 1,25(OH)2D, OCT or 19-norD2 in hemodialysis patients according to K/DOQI guidelines. Vitamin D
should not be prescribed in patients with serum concentrations of calcium and phosphate higher than those indicated. The initial doses of vi-
tamin D is related to plasma levels of PTH and then regulated on therapy outcome. K/DOQI guidelines consider the i.v. way as preferential
with respect to oral way of administration. 
To convert plasma calcium concentrations in mg/dL, multiply by 4; plasma phosphate concentrations in mg/dL, multiply by 3.1; calcium
phosphate product in mg2/dL2, multiply by 12.4.
Plasma Plasma Serum Calcium-phosphate 1,25(OH)2D OCT 19-norD2
PTH calcium phosphate product dose dose dose
(pg/mL) (mmol/L) (mmol/L) (mmol2/L2) (μg after HD) (μg after HD) (μg after HD)
300-600 <2.37 <1.78 <4.5 i.v.: 0.5-1 i.v.: 2.5-5 i.v.: 2
oral: 0.5-1 oral: 5
600-1000 <2.37 <1.78 <4.5 i.v.: 1-3 i.v.: 6-10 i.v.: 2-4
oral: 1-4 oral: 5-10
>1000 <2.5 <1.78 <4.5 i.v.: 3-5 i.v.: 10-15 i.v.: 4-8
oral: 3-7 oral: 10-20
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less potent than 1,25(OH)2D to suppress parathyroid glands
and much less active on plasma calcium. OCT is commonly
administered to hemodialysis (HD) patients three times a week
(Table III). In the first trial, episodes of hypercalcemia occurred
in 33% of patients and serum alkaline phosphatase decreased
significantly after OCT therapy, suggesting the correction of
high-turnover bone disease (104). The reduction in PTH and
the increment of calcium and phosphate were dose-dependent.
The initial OCT oral dose was 5 μg three times a week when
plasma iPTH concentration was 300-500 pg/mL and 10 μg
three times a week when iPTH was above 500 pg/mL (105).
OCT was also successfully used in CRF patients with creati-
nine clearance above 15 mL/min at the oral dose of 1-5 μg/day
with no deleterious effects on renal function (106). 
The different activity of OCT and 1,25(OH)2D has been attrib-
uted to the different pharmacokinetics of the two compounds.
OCT affinity for VDR and vitamin D-binding protein is lower
than that of 1,25(OH)2D and, thus, it is rapidly cleared from the
blood. OCT treatment is also associated with the inhibition of
renal 1α-hydroxylase and a consequent reduction in serum lev-
els of 1,25(OH)2D. The short half-life and the 1,25(OH)2D defi-
ciency explain the scarce effect of OCT on intestine and bone
and, ultimately, on calcium concentrations. On the other hand,
OCT has a prolonged activity on parathyroid glands, where it is
retained in the nuclei (107-108). 
19-norD2 has the side chain of vitamin D2 and differs from
1,25(OH)2D for the lack of carbon 22. It was the first analog ap-
proved for use in CRF patients and is available in Italy for i.v.
administration, commonly three times a week after hemodialy-
sis (Table III). It may be dosed according to a 4:1 ratio to
1,25(OH)2D, even though a ratio 3:1 was proposed for a safer
approach (109). Thus, in patients already taking 1,25(OH)2D,
the initial doses of 19-norD2 can be calculated as four times
that of 1,25(OH)2D. Alternatively, its initial dosage may be cal-
culated from circulating PTH concentrations (PTH concentra-
tion / 80) or body weight (0.04 μg/kg of dry body weight) (110). 
Efficacy of 19-norD2 and 1,25(OH)2D was compared in a ran-
domized double-blind trial. Reduction in plasma PTH was more
rapid in patient taking 19-norD2, although the PTH reduction
target (decrease of 50% of the baseline plasma concentration)
was obtained in a similar proportion of patients after 20 weeks
of treatment (79% with 19-norD2 and 69% 1,25(OH)2D). Se-
vere hyperphosphatemia (above 2.58 mmol/L or 8 mg/dL) oc-
curred in 9% of patients treated with 19-norD2 and 14% of pa-
tients treated with 1,25(OH)2D, while no differences in plasma
calcium levels were observed (111). In another randomized
double-blind study comparing 19-norD2 with 1,25(OH)2D, hy-
percalcemia and/or calcium-phosphate product above 6
mmol2/L2 (75 mg2/dL2) occurred at least once in 68% of pa-
tients during treatment with 19-norD2 and 64% with
1,25(OH)2D (112). Conversely, persistent hypercalcemia was
observed in 18% of patients treated with 19-norD2 and 33%
with 1,25(OH)2D. These trials showed that 19-norD2 was able
to control PTH levels reducing the occurrence of hypercal-
cemia and hyperphosphatemia in comparison with
1,25(OH)2D. Therefore, the control of PTH secretion is ob-
tained with lower calcium-phosphate product with 19-norD2
(111, 112). This reduces the risk of vascular calcification and
may contribute to the increased survival observed in hemodial-
ysis patients undergoing 19-norD2 therapy compared with
those taking 1,25(OH)2D (113). Furthermore, in patients taking
19-norD2 a reduced hospitalization rate was observed (114).
However, the values of these studies about survival in patients
treated with 19-norD2 was limited by the fact they were retro-
spective and not randomized.
The limited hypercalcemic effect of 19-norD2 results from a
lower affinity for VDR in intestine and bone. In addition, 19-
norD2 causes a selective vitamin D deficiency and a reduction
in intestinal calcium absorption (115, 116).
1αOHD2 is a prodrug activated by 25-hydroxylation in the liver. It
may be administered daily or three times a week, orally or i.v.
Clinical trials demonstrated a good efficacy of 1αOHD2 in the
treatment of secondary HPT in hemodialysis patients. 1αOHD2,
prescribed at the initial oral doses of 4 μg daily or three times a
week, normalized PTH concentrations in 88% of patients, but hy-
percalcemia and hyperphosphatemia complicated the treatment
in 42% and 75% of patients respectively (117). This high rate of
hypercalcemia was not observed in other studies, although an
increase in serum phosphate and calcium invariably occurred. In
a larger trial including 99 hemodialysis patients, 1αOHD2 was
prescribed at the oral dose of 10 μg three times a week. Hyper-
calcemia was observed in 15% of patients and hyperphos-
phatemia in 19%. Plasma PTH decreased by 45% from baseline
levels and became normal in 83% of patients (118). Intravenous
and oral preparations of 1αOHD2 are available. The increase of
calcium and phosphate was lower with i.v. than oral administra-
tion, but the induced decline of PTH was similar. 1αOHD2 was
also used at the dose of 1-3 μg/day in non-uremic CRF patients.
Its use was safe and effective in decreasing plasma PTH and in-
creased bone mineral density (119).
The lower hypercalcemic effect of 1αOHD2 with respect to
1αOHD3 has been attributed to the production of 24-hydroxy-
lated metabolites with less hypercalcemic activity (120). 
Conclusions
The modern strategies to prevent secondary HPT in CRF pa-
tients give great relevance to vitamin D replacement therapy,
which requires to take into account the stage of CRF, the un-
derlying renal disorder, the levels of circulating PTH, the condi-
tion of the bone, the vitamin D stores, the parameters of bone
turnover and the values of calcium and phosphate in serum. 
The administration of 1,25(OH)2D or its analogues is unavoid-
able in dialysis patients when secondary HPT is often already
established. Its association with 25(OH)D or ergocalciferol or
cholecalciferol may be beneficial for the bones, if a deficit of vi-
tamin D stores is present (serum levels of 25(OH)D below 20-
30 ng/mL). Therapeutic use of 25(OH)D or ergocalciferol is in-
dicated in earlier stages of CRF to support renal 1α-hydroxy-
lase activity. At these stages, low doses of 1,25(OH)2D may al-
so be employed to prevent HPT since they are not harmful for
renal function. The dose of vitamin D metabolites should be
titrated on serum concentrations of calcium and phosphate, to
avoid an excessively high calcium-phosphate product, and on
serum PTH concentrations, to avoid excessive PTH suppres-
sion and an adynamic condition of the bone. 
The aim of vitamin D replacement therapy is to prevent HPT
since the early stages of CRF, because parathyroid hyperpla-
sia and osteodystrophy cannot be completely reverted once
developed. The attention of nephrologists has largely focused
on dialysis patients and, unfortunately, few studies have ana-
lyzed the outcome of vitamin D therapy in non-uremic patients.
Because of the lack of clinical studies in this population no
guidelines are available on when to start vitamin D replace-
ment therapy in CRF patients. Therefore, it is likely that HPT
and osteodystrophy are undertreated in a significant proportion
of CRF patients. We have tried to summarize the criteria pro-
posed in the current literature: one common criteria is that vita-
min D therapy should be considered when serum 25(OH)D
concentration is below 30 ng/mL. Instead, we do not know
when 1,25(OH)2D can be safely prescribed to non-uremic pa-
tients and whether there are additional benefits by its associa-
tion with 25(OH)D or ergocalciferol. 
On the other hand, vitamin D therapy is not without problems,
the first of which being vascular calcification. Again, we should
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make every effort to prevent vascular calcification since the
early stages of CRF, because calcification is a non-reversible
lesion. The K/DOQI guidelines provide some criteria to mini-
mize the risk of calcium phosphate precipitation in terms of tar-
get serum concentration of calcium and phosphate. However,
our methods to fight calcification are limited and even the calci-
um-phosphate product provides insufficient information. 
The therapeutical strategies for secondary HPT are now chang-
ing. The availability of 1,25(OH)2D analogues warrants inhibi-
tion of parathyroid glands with lower effect on calcium and
phosphate levels, and perhaps reduces mortality of dialysis pa-
tients. In the near future 1,25(OH)2D analogues will be com-
bined with a new drug, cinacalcet, that directly inhibits PTH se-
cretion and parathyroid proliferation. Potentially, the associa-
tion of cinacalcet with 1,25(OH)2D or its analogues is very
promising because of the opposite effects of the two drugs on
plasma calcium levels. 
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